“Global Cell Therapy Pipeline Analysis” report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Cell Therapy based drug development process. For Report Sample Contact: rajesh@pnspharma.com

1. Global Cell Therapy Pipeline Analysis
“Global Cell Therapy Pipeline Analysis” by PNS Pharma gives comprehensive insight on the
various drugs being developed for the treatment of multiple disease based upon Cell Therapy.
Research report covers all the ongoing drug development in various development phases. Each
drug profiles include detailed information like: Originator, Owner, Collaborator, Technology
Provider, Licensee, Development Phase, Development Indications, Mechanism of Action,
Country of Development and detailed analysis on the development process. Insight for each
drug profile in development phase enables the reader to identify and understand the Cell
Therapy associated with the various diseases.
This report enables pharmaceutical companies, collaborators and other associated stake
holders to identify and analyze the available investment opportunity in the Cell Therapy
based drug development process.
For Report Sample Contact: rajesh@pnspharma.com
Following parameters for each drug profile in development phase are covered in “Global Cell
Therapy Pipeline Analysis” research report:
• Drug Profile Overview
• Alternate Names for Drug
• Active Indication
• Phase of Development
• Mechanism of Action
• Brand Name
• Orphan Designation by Indication, Country & Organisation
• Country for Clinical Trial
• Owner / Originator/ Licensee/Collaborator
• Administrative Route • Drug Class
• ATC Codes

2. Breakup of Cell Therapies by Development Phase:
• Research: 19
• Preclinical: 80
• Phase-I: 30
• Phase-I/II: 28
• Phase-II: 34
• Phase-II/III: 2
• Phase-III: 15
• Registered: 4
• Marketed: 9
For Report Sample Contact: rajesh@pnspharma.com
Each Drug Profile has Tables Representing Following Information:
• Alternate Names
• Originator & Owner
• Collaborator
• Technology Provider
• Licensee
• Highest Development Phase
• Indications
• Class
• Mechanism of Action
• ATC Code
• Designated Brand Name